A new biological role of sangivamycin; Inhibition of protein kinases.
- 1 January 1989
- journal article
- research article
- Published by Japan Antibiotics Research Association in The Journal of Antibiotics
- Vol. 42 (1) , 102-106
- https://doi.org/10.7164/antibiotics.42.102
Abstract
During the screening for the inhibitors of protein kinase C (PKC), we found that a streptomycete produced an inhibitor in our bleb-forming assay (Osada et al., J. Antibiotics 41: 925, 1988). The inhibitor was isolated and identified as sangivamycin (4-amino-5-carboxamide-7-(D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine). Biological activity of sangivamycin was compared with that of other 7-deazaadenosine group antibiotics, tubercidin and toyocamycin. Sangivamycin showed a storng inhibitory activity against bleb-formation of K562 cells and PKC. On the other hand, tubercidin and toyocamycin had only weak activities in both assays. This paper deals with a new biological activity of sangivamycin, that of an inhibitor of protein kinases, especially PKC.This publication has 7 references indexed in Scilit:
- Sangivamycin, a nucleoside analogue, is a potent inhibitor of protein kinase C.Journal of Biological Chemistry, 1988
- Rapid screening method for inhibitors of protein kinase C.The Journal of Antibiotics, 1988
- Staurosporine, a potent inhibitor of phospholipidCa++dependent protein kinaseBiochemical and Biophysical Research Communications, 1986
- A Multipotential Leukemia Cell Line (K-562) of Human OriginExperimental Biology and Medicine, 1981
- Rapid isolation of plasma membranes in high yield from cultured fibroblastsBiochemical Journal, 1977
- A NEW ANTIBIOTIC, TUBERCIDIN1957
- TOYOCAMYCIN, A NEW ANTI-CANDIDA ANTIBIOTICS1956